The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., (cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:

##STR00001##

which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:

##STR00001##

which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds. ##STR00001##

The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds. ##STR00001##

Embodiments include an electrode material including a plurality of cores fused to a plurality of redox active linkers via Aza units to form a layered two-dimensional (2D) Aza-fused pi-conjugated covalent organic framework (COF). Embodiments also include a negative electrode material including the electrode material, as well as a supercapacitor device and an asymmetric supercapacitor device including the electrode material. Embodiments further include a method of making an electrode material including one or more of the following steps: combining a hexaketocyclohexane compound and an aromatic tetraamine compound in a solution; mixing the solution including the hexaketocyclohexane compound and the aromatic tetraamine compound; and heating the mixed solution to form a 2D Aza-fused pi-conjugated COF.

Embodiments include an electrode material including a plurality of cores fused to a plurality of redox active linkers via Aza units to form a layered two-dimensional (2D) Aza-fused pi-conjugated covalent organic framework (COF). Embodiments also include a negative electrode material including the electrode material, as well as a supercapacitor device and an asymmetric supercapacitor device including the electrode material. Embodiments further include a method of making an electrode material including one or more of the following steps: combining a hexaketocyclohexane compound and an aromatic tetraamine compound in a solution; mixing the solution including the hexaketocyclohexane compound and the aromatic tetraamine compound; and heating the mixed solution to form a 2D Aza-fused pi-conjugated COF.